International medullary thyroid carcinoma grading system: an Indian tertiary care centre experience.
Grading
High grade
IMTCGS
Ki67 index
Medullary carcinoma thyroid
Mitosis
Necrosis
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
14
08
2023
accepted:
06
11
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Medullary carcinoma (MTC) is a rare neuroendocrine thyroid neoplasm. The international medullary thyroid carcinoma grading scheme (IMTCGS), which has prognostic significance, has been introduced recently. The present study graded MTC cases using the IMTCGS and evaluated it in our study cohort. All MTC thyroidectomy cases over 6 years were evaluated. Low-grade (LG) and high-grade (HG) were compared. Survival analysis included overall survival (OS), loco-regional free survival and distant metastasis free survival (DMFS). Of 32 cases, 31.25% were HG and 68.75% LG. The mean age was 44.0 years and M:F ratio 1:1.146. HG patients were older and had tumour cells with high-grade nuclear features and prominent nucleoli and showed distant metastasis. Necrosis was found more in patients with high grade nuclear features. There was discordance between the high Ki67 (60%) and increased mitotic activity (20%). Univariate survival analysis revealed poor DMFRS and OS in the cohorts with high grade, Ki67 > 5% and coagulative necrosis. The multivariate cox regression analysis showed IMTCGS significantly associated with overall survival (HR 28.30, p = 0.009) and DMFS (HR 15.70, p = 0.02). This is the first Indian study evaluating IMTCGS, a very simple and convenient grading system that can be readily used in any tertiary health care centre. IHC for Ki 67 should mandatorily be done irrespective of the low mitotic activity on the HPE and necrosis should be diligently searched in cases with high-grade nuclear morphology. HG MTC cohorts were associated with poor OS as well as DMFRS.
Identifiants
pubmed: 38010402
doi: 10.1007/s00405-023-08341-x
pii: 10.1007/s00405-023-08341-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Lloyd RV, Osamura RY, Klöppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, 4th edn. Lyon
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610
doi: 10.1089/thy.2014.0335
pubmed: 25810047
pmcid: 4490627
Barletta JA, Nosé V, Sadow PM (2021) Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocr Pathol 32(1):35–43
doi: 10.1007/s12022-021-09664-3
pubmed: 33492588
pmcid: 9353617
Horn RC (1951) Carcinoma of the thyroid: description of a distinctive morphological variant and report of seven cases. Cancer 4:697–707
doi: 10.1002/1097-0142(195107)4:4<697::AID-CNCR2820040407>3.0.CO;2-8
Hazard JB, Hawk WA, Crile G Jr (1959) Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 19:152–161
doi: 10.1210/jcem-19-1-152
pubmed: 13620740
Krampitz GW, Norton JA (2014) RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 120:1920–1931
doi: 10.1002/cncr.28661
pubmed: 24699901
Larouche V, Akirov A, Thomas CM, Krzyzanowska MK, Ezzat S (2019) A primer on the genetics of medullary thyroid cancer. Curr Oncol 26:389–394
doi: 10.3747/co.26.5553
pubmed: 31896937
pmcid: 6927790
Gogna S, Goldberg M, Samson D, Gachabayov M, Felsenreich DM, Azim A et al (2020) Medullary thyroid cancer in patients older than 45-epidemiologic trends and predictors of survival. Cancers (Basel) 12:3124
doi: 10.3390/cancers12113124
pubmed: 33114488
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK et al (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33:27–63
doi: 10.1007/s12022-022-09707-3
pubmed: 35288841
Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA et al (2022) International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol 40:96–104
doi: 10.1200/JCO.21.01329
pubmed: 34731032
Fuchs TL, Nassour AJ, Glover A, Sywak MS, Sidhu SB, Delbridge LW et al (2020) A proposed grading scheme for medullary thyroid carcinoma based on proliferative activity (Ki-67 and mitotic count) and coagulative necrosis. Am J Surg Pathol 44:1419–1428
doi: 10.1097/PAS.0000000000001505
pubmed: 32452872
pmcid: 7641183
Alzumaili B, Xu B, Spanheimer PM, Tuttle RM, Sherman E, Katabi N (2020) Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Mod Pathol 33:1690–1701
doi: 10.1038/s41379-020-0532-1
pubmed: 32313184
pmcid: 7483270
Rosai J, DeLellis RA, Carcangiu ML, Frable WJ, Tallini G et al (2015) Tumor of the thyroid and parathyroid gland (AFIP atlas of tumor pathology series 4). American Registry of Pathology Press, Silver Spring
Guyétant S, Josselin N, Savagner F, Rohmer V, Michalak S, Saint-André JP et al (2003) C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Mod Pathol 16:756–763
doi: 10.1097/01.MP.0000081727.75778.0C
pubmed: 12920219
Thomas CM, Asa SL, Ezzat S, Sawka AM, Goldstein D (2019) Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. Curr Oncol 26:338–344
doi: 10.3747/co.26.5539
pubmed: 31708652
pmcid: 6821118
Gnepp DR, Bishop JA (2020) Gnepp’s diagnostic surgical pathology of the head and neck, 3rd edn. Elsevier P, Amsterdam
Brzezinska KA, Bhardwaj S, Teng MS, Si Q, Sun J, Westra WH et al (2023) Melanotic medullary thyroid carcinoma: a case report with review of the literature. Diagn Cytopathol 51:E14–E20
doi: 10.1002/dc.25048
pubmed: 36056712
Wang C, Yun T, Wang Z, Meng N, Fan N, Lv X et al (2018) Pathological characteristics and genetic features of melanin-producing medullary thyroid carcinoma. Diagn Pathol 13:86
doi: 10.1186/s13000-018-0764-2
pubmed: 30424779
pmcid: 6234577
Singh K, Sharma MC, Jain D, Kumar R (2008) Melanotic medullary carcinoma of thyroid–report of a rare case with brief review of literature. Diagn Pathol 11:3–2
Manjunath PR, Vadayath UM, Nair V, Pavithran PV, Bhavani N, Kumar H et al (2020) Clinical profile of medullary thyroid carcinoma: audit from a tertiary care center in South India. Indian J Endocrinol Metab 24:355–359
doi: 10.4103/ijem.IJEM_329_20
pubmed: 33088760
pmcid: 7540819
Cherian AJ, Ramakant P, Pai R, Manipadam MT, Elanthenral S, Chandramohan A et al (2018) Outcome of treatment for medullary thyroid carcinoma—a single centre experience. Indian J Surg Oncol 9:52–58
doi: 10.1007/s13193-017-0718-2
pubmed: 29563735
Mehrotra PK, Mishra A, Mishra SK, Agarwal G, Agarwal A, Verma AK (2011) Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India. World J Surg 35:1273–1280
doi: 10.1007/s00268-011-1086-7
pubmed: 21479684
Giusca SE, Andriescu EC, Caruntu ID, Ciobanu D (2023) Clinicopathological profile of medullary thyroid carcinoma—could we predict aggressive behavior? Biomedicines 11:116
doi: 10.3390/biomedicines11010116
pubmed: 36672624
pmcid: 9855433
Podany P, Meiklejohn K, Garritano J, Holt EH, Barbieri A, Prasad M (2023) Grading system for medullary thyroid carcinoma; an institutional experience. Ann Diagn Pathol 64:152112
doi: 10.1016/j.anndiagpath.2023.152112
pubmed: 36736129
Vissio E, Maletta F, Fissore J, Osella Abate S, Retta F, Brizzi MP et al (2022) External validation of three available grading systems for medullary thyroid carcinoma in a single institution cohort. Endocr Pathol 33:359–370
doi: 10.1007/s12022-022-09719-z
pubmed: 35583706